Phase 1 Alzheimer's Disease Trial, Terminated NCT00874939 Sponsor: Merck Sharp & Dohme LLC Condition: Alzheimer's Disease
Back to Alzheimers Disease

Trial results

This results summary is not being shown. Voxsanity has temporarily withheld the AI generated plain English summary of these reported results. The registry and publication links are unchanged and lead to the results exactly as the sponsor reported them. How we use AI

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Phase 1 Alzheimer's Disease Trial, Terminated

NCT00874939
Terminated Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

For patients with Alzheimer's disease:

  • Women who are not able to become pregnant (not of reproductive age)
  • Men with a female partner who could become pregnant, who agree to use an approved form of birth control during the study
  • People who have completed at least 10 years of education or have a 10-year work history
  • People who have not smoked or used any nicotine products for at least 6 months
  • People who have been diagnosed with mild-to-moderate Alzheimer's disease
  • People who have a reliable caregiver who agrees to attend all clinic visits, share information with the study team, and return for all follow-up appointments

For healthy elderly volunteers:

  • People who are in good general health
  • People who have a normal heart tracing (ECG) result

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

For patients with Alzheimer's disease:

  • People who have had any other brain or nervous system condition besides Alzheimer's disease
  • People who currently live in a nursing home
  • People who have had a stroke
  • People who have had a psychotic disorder, are currently experiencing major depression, or have a history of schizophrenia
  • People who have had a sleep disorder
  • People who have had a heart or blood vessel condition
  • People who have had cancer
  • People who are currently or have previously taken part in a study involving an experimental treatment, device, or vaccine for Alzheimer's disease
  • People who drink more than 6 caffeinated drinks (such as coffee, tea, or cola) per day
  • People who drink more than 3 alcoholic drinks per day
  • People who have had major surgery, or who have donated or lost blood in the past 8 weeks

For healthy elderly volunteers:

  • People who have significant mental health difficulties, emotional problems, or a history of a psychiatric condition in the past 5–10 years, or who are not able to make their own decisions legally or mentally

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 August 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Terminated
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
6 April 2009
Est. completion
20 April 2009

Primary endpoints

Time Weighted Average of the Change From Baseline After Single Dose Administration of Donepezil 5 mg or Placebo, Measured by Groton Maze Learning Test (GMLT) in Participants With Alzheimer's Disease; Time Weighted Average of the Change From Baseline After Single Dose Administration of Donepezil 5 mg or Placebo, Measured by Groton Maze Learning Test (GMLT) in Healthy Participants

Other options

Expanded access pathways

This trial is not enrolling. Other access pathways exist in general: in Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients. Whether it applies to any treatment studied here is a question for your doctor — nothing on this page says it does.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov